Algen, a spin-out from Nobel laureate Jennifer Doudna’s lab, is revolutionizing therapeutic drug discovery through advanced CRISPR gene-modulation and AI. Backed by Viking Global Investors, Algen is on the mission to reverse-engineer human diseases to find a new paradigm of medicine that could change the course of cancer and inflammation. Its proprietary platform AlgenBrain integrates advanced deep learning models with scalable, single-cell CRISPR systems to decode causal disease biology and accelerate the development of next-generation therapies. Algen recently established a $555 million multi-target partnership with AstraZeneca to advance AI-powered drug discovery in immunology.